Sanofi SA (NYSE:SNY)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a research note issued to investors on Friday.

A number of other equities analysts have also recently weighed in on the stock. Argus reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sanofi SA in a research report on Friday, September 1st. HSBC Holdings plc raised shares of Sanofi SA from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub raised shares of Sanofi SA from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price objective (up previously from $46.00) on shares of Sanofi SA in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised shares of Sanofi SA from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $54.00.

Sanofi SA (NYSE SNY) traded down 0.55% during mid-day trading on Friday, hitting $48.45. 1,843,521 shares of the stock traded hands. The stock has a market cap of $121.68 billion, a P/E ratio of 11.54 and a beta of 0.88. The stock has a 50-day moving average price of $48.29 and a 200-day moving average price of $47.28. Sanofi SA has a 12 month low of $36.81 and a 12 month high of $50.24.

Sanofi SA (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74. The company had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities analysts forecast that Sanofi SA will post $3.34 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “J P Morgan Chase & Co Reaffirms Neutral Rating for Sanofi SA (SNY)” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/15/j-p-morgan-chase-co-reaffirms-neutral-rating-for-sanofi-sa-sny.html.

In other Sanofi SA news, major shareholder Sanofi purchased 60,595 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, with a total value of $29,023,793.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.00% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Founders Financial Securities LLC purchased a new position in Sanofi SA in the 2nd quarter valued at approximately $907,000. Goodwin Daniel L purchased a new position in Sanofi SA in the 2nd quarter valued at approximately $239,000. Wellington Management Group LLP purchased a new position in Sanofi SA in the 1st quarter valued at approximately $2,252,000. Stifel Financial Corp boosted its position in Sanofi SA by 8.6% in the 1st quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares during the period. Finally, Bluestein R H & Co. boosted its position in Sanofi SA by 7.5% in the 1st quarter. Bluestein R H & Co. now owns 21,500 shares of the company’s stock valued at $973,000 after buying an additional 1,500 shares during the period. 9.33% of the stock is owned by institutional investors.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (NYSE:SNY)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.